SNX3 and pemphigus foliaceus: SNX3 upregulation in AT2 cells drives fibrotic progression, while its knockout or pharmacological inhibition by the novel TDN-LC4 nanodrug attenuates Wnt/β-catenin signaling, fibrosis, and lung dysfunction, offering a multi-target therapeutic strategy for PF.